Moisture-resistant, sterilizable and reusable N-95 like piezoelectric facemask filtering membrane with long-term biodegradability

防潮、可灭菌、可重复使用的N-95类压电口罩过滤膜,具有长期生物降解性

基本信息

  • 批准号:
    10547176
  • 负责人:
  • 金额:
    $ 27.64万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-09-01 至 2023-08-31
  • 项目状态:
    已结题

项目摘要

Abstract Facemasks have been shown to be the most effective tool to prevent the spreading and transmission of infectious viruses in pandemics. Many countries, including the US, have enforced the use of facemasks in public area or healthcare settings to protect healthcare workers and general population against highly contagious viral strains of the SARS-COVID-2. This global enforcement of facemasks has led to billions of N95/surgical masks (which are intended for single-use and are non-degradable) being disposed of in landfills and ocean, causing a significant crisis on the environment. Aside from viral infection, particulate matters (PMs, i.e. small particles with sizes at nano or micro-meters) from the combustion of fossil fuels around the world also has severe impact on human health. Especially, small particles such as PM1.0 or PM2.5 (i.e. sizes < 1 µm and 2.5 µm, respectively) are the most poisonous and harmful ones since they can travel into deeper parts of the respiratory tract and even penetrate into the bloodstream. In this regard, facemasks have also been the most effective solution to protect public health from industrial PMs and air pollution. Given such a tremendous demand of filtration facemask membranes, the heavy and continuous use of traditional non-degradable, one-time disposable facemasks (e.g. N95 and surgical masks) will not only be an economic burden but also cause an environmental crisis with billions of permanent plastic wastes disposed every year. Besides the environmental problem, current facemasks struggle with a significant drawback of losing filtration function after a long period of continuous use and exposure of humid air, thus making the mask users non-protective against the risk of viral infection. Herein, we propose a novel piezoelectric composite nanofiber mesh of Poly-L-Lactide (PLLA) and Magnesium Oxide (MgO) which provides all properties of an ideal filtering membrane, including (1) moisture- resistance, (2) good mechanical strength, (3) N95-like filtering efficiency, (4) small pressure-drop, (5) reusability/sterilize-ability, and (6) long-term biodegradation to avoid any harm on the environment. Our major hypothesis is that by creating a highly piezoelectric MgO/PLLA and then employ multi-layer of the MgO/PLLA nanofiber mesh with tunable pore size/pore number in each layer, we will be able to produce a desired filter with a high filtration efficiency and low pressure drop, similar to a N95 facemask filter. To achieve the facemask and demonstrate the hypothesis in this phase I SBIR, we design the project with two aims. Aims 1 (6 months) is to characterize the MgO/PLLA nanofiber membrane filter in terms of piezoelectric effect, mechanical property, and porosity of the nanofiber membrane. Aim 2 (12 months) is to fabricate the multi-layer filtering membrane with the MgO/PLLA nanofiber mesh patterned with micro-pores and achieve the N-95 performance in terms of filtering efficiency and pressure drop.
摘要 口罩已被证明是防止传染病传播和传播的最有效工具。 流行病中的病毒包括美国在内的许多国家都强制在公共场所或公共场所使用口罩。 保护医护人员和一般人群免受高传染性病毒株的感染 关于SARS-COVID-2全球对口罩的强制执行导致数十亿个N95/外科口罩( 一次性使用,不可降解)被丢弃在垃圾填埋场和海洋中, 对环境的重大危机。除了病毒感染外,颗粒物质(PM,即具有 纳米或微米尺寸)的化石燃料燃烧也对世界各地的 人体健康特别是小颗粒,如PM1.0或PM2.5(即尺寸分别< 1 µm和2.5 µm) 是最有毒和有害的,因为它们可以进入呼吸道的更深处, 甚至渗透到血液中在这方面,口罩也是最有效的解决方案, 保护公众健康免受工业PM和空气污染的影响。考虑到如此巨大的过滤需求 面膜膜,传统的重和连续使用不可降解,一次性使用 口罩(例如N95和外科口罩)不仅会造成经济负担,还会造成环境污染。 每年有数十亿的永久性塑料废物被处理。除了环境问题,目前 面罩在长时间连续使用后会失去过滤功能 以及暴露在潮湿空气中,从而使口罩使用者不能保护免受病毒感染的风险。在此, 本文提出了一种新型的聚L-丙交酯(PLLA)和镁的压电复合网格 氧化物(MgO),其提供理想过滤膜的所有特性,包括(1)水分- 阻力,(2)良好的机械强度,(3)类似N95的过滤效率,(4)小的压降,(5) 可重复使用性/灭菌能力,以及(6)长期生物降解以避免对环境的任何危害。我们 主要的假设是,通过创建一个高度压电MgO/PLLA,然后采用多层的 MgO/PLLA多孔网,每层孔径/孔数可调,我们将能够生产出 具有高过滤效率和低压降的理想过滤器,类似于N95面罩过滤器。实现 在第一阶段SBIR中,我们设计了两个目标的项目。旨在 1(6个月)是在压电效应方面表征MgO/PLLA隔膜过滤器, 机械性能和多孔性。目标2(12个月)是制造多层 用MgO/PLLA复合网格图案化微孔过滤膜,并达到N-95 在过滤效率和压降方面的性能。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Linh Le其他文献

Linh Le的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Linh Le', 18)}}的其他基金

Integrating New York State's Prescription Drug Monitoring Program (PDMP)
整合纽约州的处方药监测计划 (PDMP)
  • 批准号:
    8716115
  • 财政年份:
    2013
  • 资助金额:
    $ 27.64万
  • 项目类别:

相似国自然基金

通过ubi1内含子改造提高单子叶植物外源基因表达
  • 批准号:
    30970231
  • 批准年份:
    2009
  • 资助金额:
    35.0 万元
  • 项目类别:
    面上项目
基于安全多方计算的抗强制电子选举协议研究
  • 批准号:
    60773114
  • 批准年份:
    2007
  • 资助金额:
    28.0 万元
  • 项目类别:
    面上项目

相似海外基金

Phase Ib/II study of safety and efficacy of EZH2 inhibitor, tazemetostat, and PD-1 blockade for treatment of advanced non-small cell lung cancer
EZH2 抑制剂、他泽美司他和 PD-1 阻断治疗晚期非小细胞肺癌的安全性和有效性的 Ib/II 期研究
  • 批准号:
    10481965
  • 财政年份:
    2024
  • 资助金额:
    $ 27.64万
  • 项目类别:
CCA's lineage heterogeneity and subsequent adaptive reprogramming upon acquired resistant to CDK4/6 inhibitor.
CCA 的谱系异质性以及随后获得对 CDK4/6 抑制剂耐药性后的适应性重编程。
  • 批准号:
    24K18491
  • 财政年份:
    2024
  • 资助金额:
    $ 27.64万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Designing Rational Combinations to Improve CAR T Cell Therapy for Prostate Cancer
设计合理的组合以改善前列腺癌的 CAR T 细胞疗法
  • 批准号:
    10752046
  • 财政年份:
    2024
  • 资助金额:
    $ 27.64万
  • 项目类别:
Greatwall in replication stress/DNA damage responses and oral cancer resistance
长城在复制应激/DNA损伤反应和口腔癌抵抗中的作用
  • 批准号:
    10991546
  • 财政年份:
    2024
  • 资助金额:
    $ 27.64万
  • 项目类别:
AMPQuest - Journeying to new horizons in treating drug-resistant infections.
AMPQuest - 迈向治疗耐药感染的新视野。
  • 批准号:
    BB/Y514019/1
  • 财政年份:
    2024
  • 资助金额:
    $ 27.64万
  • 项目类别:
    Research Grant
Indication selection, patient stratification, and IND preparation for STX-002: the first-in-class LRG1 inhibitor for treatment of chronic kidney disease and immunotherapy-resistant tumours.
STX-002的适应症选择、患者分层和IND准备:用于治疗慢性肾病和免疫治疗耐药肿瘤的一流LRG1抑制剂。
  • 批准号:
    10092585
  • 财政年份:
    2024
  • 资助金额:
    $ 27.64万
  • 项目类别:
    Collaborative R&D
Creation of CAR-Tregs that are resistant to the senescent environment
创造抵抗衰老环境的 CAR-Tr​​eg
  • 批准号:
    BB/X009610/1
  • 财政年份:
    2024
  • 资助金额:
    $ 27.64万
  • 项目类别:
    Research Grant
Parent-adolescent informant discrepancies: Predicting suicide risk and treatment outcomes
父母与青少年信息差异:预测自杀风险和治疗结果
  • 批准号:
    10751263
  • 财政年份:
    2024
  • 资助金额:
    $ 27.64万
  • 项目类别:
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 27.64万
  • 项目类别:
    Research Grant
Role of Slc5a5 in the diagnosis and treatment of drug-resistant cancer
Slc5a5在耐药癌症诊断和治疗中的作用
  • 批准号:
    24K10435
  • 财政年份:
    2024
  • 资助金额:
    $ 27.64万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了